The role of carbon monoxide and heme oxygenase in the prevention of sickle cell disease vaso-occlusive crises

American Journal of Hematology

Volumn 92, Issue 6, 2017, Pages 569-582

  Gomperts, Edward ^a   Belcher, John D ^b   Otterbein, Leo E ^c   Coates, Thomas D ^d   Wood, John ^d   Skolnick, Brett E ^a   Levy, Howard ^a   Vercellotti, Gregory M ^b  

^a Hillhurst Biopharmaceuticals Inc   (United States)

^b UNIVERSITY OF MINNESOTA   (United States)

^c BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^d CHILDREN S HOSPITAL LOS ANGELES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARBON MONOXIDE; GASOTRANSMITTER; HEME; HEME OXYGENASE; HEMOGLOBIN;

ANTIINFLAMMATORY ACTIVITY; ANTIOXIDANT ACTIVITY; APOPTOSIS; BLOOD FLOW; CELL ADHESION; CEREBROVASCULAR DISEASE; DRUG SAFETY; HUMAN; IN VITRO STUDY; NONHUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PRECLINICAL STUDY; PRIORITY JOURNAL; REVIEW; RISK BENEFIT ANALYSIS; SICKLE CELL ANEMIA; SIGNAL TRANSDUCTION; VASCULAR ENDOTHELIUM; VASODILATATION; ANEMIA, SICKLE CELL; ANIMAL; BLOOD; CHEMISTRY; CLINICAL TRIAL (TOPIC); COMPLICATION; DISEASE MODEL; GENETICS; METABOLISM; TREATMENT OUTCOME; VASCULAR DISEASES;

ANEMIA, SICKLE CELL; ANIMALS; CARBON MONOXIDE; CLINICAL TRIALS AS TOPIC; DISEASE MODELS, ANIMAL; HEME OXYGENASE (DECYCLIZING); HEMOGLOBINS; HUMANS; SIGNAL TRANSDUCTION; TREATMENT OUTCOME; VASCULAR DISEASES;

EID: 85018949420     PISSN: 03618609     EISSN: 10968652     Source Type: Journal    
DOI: 10.1002/ajh.24750     Document Type: Review

References (169)

1. Hebbel RP. Reconstructing sickle cell disease: a data-based analysis of the “hyperhemolysis paradigm” for pulmonary hypertension from the perspective of evidence-based medicine. Am J Hematol. 2011;86:123–154.
2. Cooper CE, Schaer DJ, Buehler PW, et al. Haptoglobin binding stabilizes hemoglobin ferryl iron and the globin radical on tyrosine beta145. Antioxid Redox Signal. 2013;18:2264–2273.
3. Moestrup SK, Moller HJ. CD163: a regulated hemoglobin scavenger receptor with a role in the anti-inflammatory response. Annal Med. 2004;36:347–354.
4. Nielsen MJ, Moller HJ, Moestrup SK. Hemoglobin and heme scavenger receptors. Antioxid Redox Signal. 2010;12:261–273.
5. Muller-Eberhard U, Javid J, Liem HH, Hanstein A, Hanna M. Plasma concentrations of hemopexin, haptoglobin and heme in patients with various hemolytic diseases. Blood. 1968;32:811–815.
6. Reiter CD, Wang X, Tanus-Santos JE, et al. Cell-free hemoglobin limits nitric oxide bioavailability in sickle-cell disease. Nat Med. 2002;8:1383–1389.
7. Morris CR, Gladwin MT, Kato GJ. Nitric oxide and arginine dysregulation: a novel pathway to pulmonary hypertension in hemolytic disorders. Curr Mol Med. 2008;8:620–632.
8. Belcher JD, Chen C, Nguyen J, et al. Heme triggers TLR4 signaling leading to endothelial cell activation and vaso-occlusion in murine sickle cell disease. Blood. 2014;123:377–390.
9. Bunn HF, Jandl JH. Exchange of heme among hemoglobins and between hemoglobin and albumin. J Biol Chem. 1968;243:465–475.
10. Umbreit J. Methemoglobin–it's not just blue: a concise review. Am J Hematol. 2007;82:134–144.
11. Hrkal Z, Vodrazka Z, Kalousek I. Transfer of heme from ferrihemoglobin and ferrihemoglobin isolated chains to hemopexin. Eur J Biochem. 1974;43:73–78.
12. Hvidberg V, Maniecki MB, Jacobsen C, Hojrup P, Moller HJ, Moestrup SK. Identification of the receptor scavenging hemopexin-heme complexes. Blood. 2005;106:2572–2579.
13. Smith A, Morgan WT. Haem transport to the liver by haemopexin. Receptor-mediated uptake with recycling of the protein. Biochem J. 1979;182:47–54.
14. Balla J, Jacob HS, Balla G, Nath K, Eaton JW, Vercellotti GM. Endothelial-cell heme uptake from heme proteins: induction of sensitization and desensitization to oxidant damage. Proc Natl Acad Sci U S A. 1993;90:9285–9289.
15. Belcher JD, Marker PH, Geiger P, et al. Low-density lipoprotein susceptibility to oxidation and cytotoxicity to endothelium in sickle cell anemia. J Lab Clin Med. 1999;133:605–612.
16. Camus SM, De Moraes JA, Bonnin P, et al. Circulating cell membrane microparticles transfer heme to endothelial cells and trigger vasoocclusions in sickle cell disease. Blood. 2015;125:3805–3814.
17. Hanson MS, Piknova B, Keszler A, et al. Methaemalbumin formation in sickle cell disease: effect on oxidative protein modification and HO-1 induction. Br J Haematol. 2011;154:502–511.
18. Balla G, Jacob HS, Eaton JW, Belcher JD, Vercellotti GM. Hemin: a possible physiological mediator of low density lipoprotein oxidation and endothelial injury. Arterioscler Thromb. 1991;11:1700–1711.
19. Dutra FF, Alves LS, Rodrigues D, et al. Hemolysis-induced lethality involves inflammasome activation by heme. Proc Natl Acad Sci USA. 2014;111:E4110–E4118.
20. Figueiredo RT, Fernandez PL, Mourao-Sa DS, et al. Characterization of heme as activator of Toll-like receptor 4. J Biol Chem. 2007;282:20221–20229.
21. Jeney V, Balla J, Yachie A, et al. Pro-oxidant and cytotoxic effects of circulating heme. Blood. 2002;100:879–887.
22. Porto BN, Alves LS, Fernandez PL, et al. Heme induces neutrophil migration and reactive oxygen species generation through signaling pathways characteristic of chemotactic receptors. J Biol Chem. 2007;282:24430–24436.
23. Ghosh S, Ihunnah CA, Hazra R, et al. Nonhaemopoietic Nrf2 dominantly impedes adult progression of sickle cell anemia in mice. JCI Insight. 2016;1: pii:epub 2016 Apr 7.
24. Hidalgo A, Chang J, Jang JE, Peired AJ, Chiang EY, Frenette PS. Heterotypic interactions enabled by polarized neutrophil microdomains mediate thromboinflammatory injury. Nat Med. 2009;15:384–391.
25. Li J, Kim K, Hahm E, et al. Neutrophil AKT2 regulates heterotypic neutrophil-platelet interactions during vascular inflammation. J Clin Invest. 2014;124:1483–1496.
26. Manwani D, Frenette PS. Vaso-occlusion in sickle cell disease: pathophysiology and novel targeted therapies. Blood. 2013;122:3892–3898.
27. Turhan A, Weiss LA, Mohandas N, Coller BS, Frenette PS. Primary role for adherent leukocytes in sickle cell vascular occlusion: a new paradigm. Proc Natl Acad Sci U S A. 2002;99:3047–3051.
28. Zhang D, Chen G, Manwani D, et al. Neutrophil ageing is regulated by the microbiome. Nature. 2015;525:528–532.
29. Osarogiagbon RU, Choong S, Belcher JD, Vercellotti GM, Paller MS, Hebbel RP. Reperfusion injury pathophysiology in sickle transgenic mice. Blood. 2000;96(1):314–320.
30. Hebbel RP, Osarogiagbon R, Kaul D. The endothelial biology of sickle cell disease: inflammation and a chronic vasculopathy. Microcirculation. 2004;11:129–151.
31. Rees DC, Williams TN, Gladwin MT. Sickle cell disease. Lancet. 2010;76:2018–2031.
32. Embury SH, Hebbel RP, Mohandas N, Steinberg MH. Sickle Cell Disease: Basic Principles and Clinical Practice. New York: Raven Press; 1994.
33. Gardner K, Douiri A, Drasar E, et al. Survival in adults with sickle cell disease in a high-income setting. Blood. 2016; 28(10):1436–1438.
34. Platt OS, Rosenstock W, Espeland MA. Influence of sickle hemoglobinopathies on growth and development. N Engl J Med. 1984;311:7–12.
35. Pleasants S. A moving target. Nature. 2014;515:S2
36. National Heart, Lung, and Blood Institute. Disease and conditions index. Sickle cell anemia: who is at risk? Bethesda, MD: US Department of Health and Human Services, National Institutes of Health, National Heart, Lung, and Blood Institute; 2016. Available from: https://www.nhlbi.nih.gov/health/health-topics/topics/sca/atrisk.
37. Haemoglobinopathies on the Move. Is Europe ready? Health and Migration Policy Perspectives. http://www.enerca.org and http://www.thalassaemia.org.cy.
38. Piel FB, Hay SI, Gupta S, Weatherall DJ, Williams TN. Global burden of sickle cell anaemia in children under five, 2010-2050: modelling based on demographics, excess mortality, and interventions. PLoS Med. 2013;10(7):e1001484
39. Telen MJ. Beyond hydroxyurea: new and old drugs in the pipeline for sickle cell disease. Blood. 2016;127:810–819.
40. Motterlini R, Otterbein LE. The therapeutic potential of carbon monoxide. Nat Rev Drug Discov. 2010;9(9):728–743.
41. Foresti R, Bani-Hani MG, Motterlini R. Use of carbon monoxide as a therapeutic agent: promises and challenges. Intensive Care Med. 2008;34:649–658.
42. Balla G, Vercellotti G, Eaton JW, Jacob HS. Heme uptake by endothelium synergizes polymorphonuclear granulocyte-mediated damage. Trans Assoc Am Physicians. 1990;103:174–179.
43. Otterbein LE, Soares MP, Yamashita K, Bach FH. Heme oxygenase-1: unleashing the protective properties of heme. Trends Immunol. 2003;24(8):449–455.
44. Foresti R, Goatly H, Green CJ, Motterlini R. Role of heme oxygenase-1 in hypoxia-reoxygenation: requirement of substrate heme to promote cardioprotection. Am J Physiol Heart Circ Physiol. 2001;281(5):H1976–H1984.
45. Abraham NGJH-C, Lin ML, Schwartzman RD, Levere, Amd S. Shibahara The physiological significance of heme oxygenase. Int J Biochem. 1988;20:543–558.
46. Camhi SL, Alam J, Otterbein LE, Sylvester SL, Choi AMK. Induction of heme oxygenase-1 gene expression by lipopolysaccharide is mediated by AP-1 activation. Am J Respir Cell Mol Biol. 1995;13:387–398.
47. Maines MD. The heme oxygenase system: A regulator of second messenger gases. Annu Rev Pharmacol Toxicol. 1997;37:517–554.
48. Applegate LA, Luscher P, Tyrell RM. Induction of heme oxygenase: A general response to oxidant stress in cultured mammalian cells. Cancer Res. 1991;51:974–978.
49. Keyse SM, Tyrell RM. Heme oxygenase is the major 32-kDa stress protein induced in human skin fibroblasts by UVA radiation, hydrogen peroxide, and sodium arsenite. Proc Natl Acad Sci USA. 1989;86:99–103.
50. Lee PJ, Alam J, Sylvester SL, Imamdar N, Otterbein LE, Choi AMK. Regulation of heme oxygenase-1 expression in vivo and in vitro in hyperoxic lung injury. Am J Respir Cell Mol Biol. 1996;14:556–568.
51. Belcher JD, Young M, Chen C, et al. MP4CO, a pegylated hemoglobin saturated with carbon monoxide, is a modulator of HO-1, inflammation and vaso-occlusion in transgenic sickle cell mice. Blood. 2013;122:2757–2764.
52. Renkens JJ, Rouflart MM, Christiaans MH, van den Berg-Loonen EM, van Hooff JP, van Heurn LW. Outcome of nonheart-beating donor kidneys with prolonged delayed graft function after transplantation. Am J Transplant. 2005;5(11):2704–2709.
53. Tenhunen R, Marver HS, Schmidt R. The enzymatic catabolism of hemoglobin: stimulation of microsomal heme oxygenase by hemin. J Lab Clin Med. 1970;75:410–421.
54. Otterbein LE, Bach FH, Alam J, et al. Carbon monoxide has anti-inflammatory effects involving the mitogen-activated protein kinase pathway. Nat Med. 2000;4: 422–428.
55. Kim KM, Pae HO, Zheng M, Park R, Kim YM, Chung HT. Carbon monoxide induces heme oxygenase-1 via activation of protein kinase R-like endoplasmic reticulum kinase and inhibits endothelial cell apoptosis triggered by endoplasmic reticulum stress. Circ Res. 2007;101(9):919–927.
56. Chi PL, Lin CC, Chen YW, Hsiao LD, Yang CM. CO Induces Nrf2-dependent heme oxygenase-1 transcription by cooperating with sp1 and c-jun in rat brain astrocytes. Mol Neurobiol. 2015;52(1):277–292.
57. Shin DY, Chung J, Joe Y, et al. Pretreatment with CO-releasing molecules suppresses hepcidin expression during inflammation and endoplasmic reticulum stress through inhibition of the STAT3 and CREBH pathways. Blood. 2012;119(11):2523–2532.
58. Morse D, Lin L, Choi AM, Ryter SW. Heme oxygenase-1, a critical arbitrator of cell death pathways in lung injury and disease. Free Radic Biol Med. 2009;47(1):1–12.
59. Chung J, Shin DY, Zheng M, et al. Carbon monoxide, a reaction product of heme oxygenase-1, suppresses the expression of C-reactive protein by endoplasmic reticulum stress through modulation of the unfolded protein response. Mol Immunol. 2011;48(15-16):1793–1799.
60. Sawle P, Foresti R, Mann BE, Johnson TR, Green CJ, Motterlini R. Carbon monoxide-releasing molecules (CO-RMs) attenuate the inflammatory response elicited by lipopolysaccharide in RAW264.7 murine macrophages. Br J Pharmacol. 2005;145(6):800–810.
61. Zhang X, Shan P, Alam J, Fu XY, Lee PJ. Carbon monoxide differentially modulates STAT1 and STAT3 and inhibits apoptosis via a phosphatidylinositol 3-kinase/Akt and p38 kinase-dependent STAT3 pathway during anoxia-reoxygenation injury. J Biol Chem. 2005;280(10):8714–8721.
62. Stewart RD. The effect of carbon monoxide on humans. Annu Rev Pharmacol. 1975;15:409–423.
63. Wilbur S, Williams M, Williams R, et al. Toxicological Profile for Carbon Monoxide. Atlanta (GA): Agency for Toxic Substances and Disease Registry (US); Jun. 2012.
64. World Health Organization, “Environmental Health Criteria 213. Carbon Monoxide (Second Edition),” ISBN 92 4 157213 2, Geneva, 1999.
65. Levitt DG, Levitt MD. Carbon monoxide: a critical quantitative analysis and review of the extent and limitations of its second messenger function. Clin Pharmacol. 2015;7:37–56.
66. Prabhakar NR, Dinerman JL, Agani FH, Snyder SH. Carbon monoxide: A role in carotid body chemoreception. Proc Natl Acad Sci USA. 1995;92:1994–1997.
67. Sato K, Balla J, Otterbein L, et al. Carbon monoxide generated by heme oxygenase-1 suppresses the rejection of mouse-to-rat cardiac transplants. J Immunol. 2001;166:4185–4194.
68. Otterbein LE, Mantell LL, Choi AM. Carbon monoxide provides protection against hyperoxic lung injury. Am J Physiol. 1999;276:L688–L694.
69. Zeynalov E, Dore S. Low doses of carbon monoxide protect against experimental focal brain ischemia. Neurotox Res. 2009;15:133–137.
70. Kuramitsu K, Gallo D, Yoon M, et al. Carbon monoxide enhances early liver regeneration in mice after hepatectomy. Hepatology. 2011;53:2016–2026.
71. Schallner N, Pandit R, LeBlanc R, 3rd, et al. Microglia regulate blood clearance in subarachnoid hemorrhage by heme oxygenase-1. J Clin Invest. 2015;125:2609–2615.
72. Fujita T, Toda K, Karimova A, et al. Paradoxical rescue from ischemic lung injury by inhaled carbon monoxide driven by derepression of fibrinolysis. Nat Med. 2001;7:598–604.
73. Aroutiounian SK, Louderback JG, Ballas SK, Kim-Shapiro DB. Evidence for carbon monoxide binding to sickle cell polymers during melting. Biophys Chem. 2001;91(2):167–181.
74. Chung LL, Magdorff-Fairchild B. Extent of polymerization in partially liganded sickle hemoglobin. Arch Biochem Biophys. 1978;189(2):535–539.
75. Sirs JA. The use of carbon monoxide to prevent sickle-cell formation. Lancet. 1963;1:971–972.
76. Higgins JM, Eddington DT, Bhatia SN, Mahadevan L. Sickle cell vaso-occlusion and rescue in a microfluidic device. Proc Natl Acad Sci USA. 2007;104:20496–20500.
77. Vandorpe DH1, Xu C, Shmukler BE, et al. Hypoxia activates a Ca2+-permeable cation conductance channel sensitive to CO and to GsMTx-4 in human and mouse sickle erythrocytes. PLoS One. 2010;5(1):e8732
78. Meng F, Alayash AI. Determination of extinction coefficients of human hemoglobin in various redox states. Anal Biochem. 2017;521:11–19. doi: 10.1016/j.ab.2017.01.002. Epub 2017 Jan 6.
79. Kassa T, Jana S, Meng F, Alayash AI. Differential heme release from various hemoglobin redox states and the upregulation of cellular heme oxygenase-1. FEBS Open Bio. 2016;6(9):876–884.
80. Nakahira K, Kim HP, Geng XH, et al. Carbon monoxide differentially inhibits TLR signaling pathways by regulating ROS-induced trafficking of TLRs to lipid rafts. J Exp Med. 2006;2;203(10):2377–2389.
81. Chin BY, Jiang G, Wegiel B, et al. Hypoxia-inducible factor 1alpha stabilization by carbon monoxide results in cytoprotective preconditioning. Proc Natl Acad Sci U S A. 2007;104(12):5109–5114.
82. Bilban M, Bach FH, Otterbein SL, et al. Carbon monoxide orchestrates a protective response through PPARgamma. Immunity. 2006;24(5):601–610.
83. Bilban M, Haschemi A, Wegiel B, Chin BY, Wagner O, Otterbein LE. Heme oxygenase and carbon monoxide initiate homeostatic signaling. J Mol Med. 2008;86(3):267–279.
84. Haschemi A, Chin BY, Jeitler M, et al. Carbon monoxide induced PPARγ SUMOylation and UCP2 block inflammatory gene expression in macrophages. PLoS One. 2011;6(10):e26376
85. Belcher JD, Vineyard JV, Bruzzone CM, et al. Heme-oxygenase-1 gene delivery by Sleeping Beauty inhibits vascular stasis in a murine model of sickle cell disease. J Mol Med. 2010;88:665–675.
86. Beutler E. The effect of carbon monoxide on red cell life span in sickle cell disease. Blood. 1975;46:253–259.
87. Yallop D, Duncan ER, Norris E, et al. The associations between air quality and the number of hospital admissions for acute pain and sickle-cell disease in an urban environment. Br J Haematol. 2007;136(6):844–848.
88. Mahan VL. Neuroprotective, neurotherapeutic and neurometabolic effects of corbon monoxide. Med Gas Res. 2012;2:32–36.
89. Howard J, Thein SL, Galactéros F, Inati A, Reid ME, Keipert PE, Small T, Booth F. Safety and tolerability of MP4CO: A Dose escalation study in stable patients with sickle cell disease. Am Soc Hematol. 2014. [Abstract]
90. Misra H, Bainbridge J, Berryman J, et al. A phase 1b open label, randomized, safety study of SANGUINATE in patients with sickle cell anemia. Braz J Hematol Hemother. 2017;39: 20–27.
91. Misra H, Lickliter J, Kazo F, Abuchowski A. PEGylated carboxyhemoglobin bovine (SANGUINATE): results of a phase I clinical trial. Artif Organs. 2014;38(8):702–707. Doi: 10.1111/aor.12341
92. Bathoorn E, Slebos DJ, Postma DS, et al. Anti-inflammatory effects of inhaled carbon monoxide in patients with COPD: a pilot study. Eur Respir J. 2007;30:1131–1137.
93. Mayr FB, Spiel A, Leitner J, et al. Effects of carbon monoxide inhalation during experimental endotoxemia in humans. Am J Respir Crit Care Med. 2005;171(4):354–360. Epub 2004 Nov 19.
94. Rhodes MA, Carraway MS, Piantadosi CA, et al. Carbon monoxide, skeletal muscle oxidative stress, and mitochondrial biogenesis in humans. Am J Physiol Heart Circ Physiol. 2009;297(1):H392–H399.
95. DeBaun MR, Kirkham FJ. Central nervous system complications and management in sickle cell disease. Blood. 2016;127:829–838.
96. Schatz J, Brown RT, Pascual JM, Hsu L, Debaum MR. Poor school and cognitive functioning with silent cerebral infarcts and sickle cell disease. Neurology. 2001;56:1109–1111.
97. Brüne B, Ullrich V. Inhibition of platelet aggregation by carbon monoxide is mediated by activation of guanylate cyclase. Mol Pharmacol. 1987;32(4):497–504.
98. Stone JR, Marletta MA. Soluble guanylate cyclase from bovine lung: activation with nitric oxide and carbon monoxide and spectral characterization of the ferrous and ferric states. Biochemistry. 1994; 33(18):5636–5640.
99. Liu XM, Chapman GB, Peyton KJ, Schafer AI, Durante W. Carbon monoxide inhibits apoptosis in vascular smooth muscle cells. Cardiovasc Res. 2002;55(2):396–405.
100. Li MH, Cha YN, Surh YJ. Carbon monoxide protects PC12 cells from peroxynitrite-induced apoptotic death by preventing the depolarization of mitochondrial transmembrane potential. Biochem Biophys Res Commun. 2006;342(3):984–990.
101. Kim HS, Loughran PA, Kim PK, Billiar TR, Zuckerbraun BS. Carbon monoxide protects hepatocytes from TNF-alpha/Actinomycin D by inhibition of the caspase-8-mediated apoptotic pathway. Biochem Biophys Res Commun. 2006;344(4):1172–1178.
102. Wang X, Wang Y, Kim HP, Nakahira K, Ryter SW, Choi AM. Carbon monoxide protects against hyperoxia-induced endothelial cell apoptosis by inhibiting reactive oxygen species formation. J Biol Chem. 2007;282(3):1718–1726.
103. Vieira HL, Queiroga CS, Alves PM. Preconditioning indiced by carbon monoxide provides neuronal protection against apoptosis. J Neurochem. 2008;107:375–384.
104. Queiroga CSF, Vercelli A, Vieira HLA. Carbon monoxide and the CNS: challenges and achievements. Br J Pharmacol. 2015;172: 1533–1545.
105. Almeida AS, Queiroga CS, Sousa MF, Alves PM, Vieira HL. Carbon monoxide modulates apoptosis by reinforcing oxidative metabolism in astrocytes: role of Bcl-2. J Biol Chem. 2012;287:10762–10770.
106. Ferreira A, Marguti I, Bechmann I, et al. Sickle hemoglobin confers tolerance to Plasmodium infection. Cell. 2011;145: 398–409.
107. Wang XM, Kim HP, Nakahira K, Ryter SW, Choi AM. The heme oxygenase-1/carbon monoxide pathway suppresses TLR4 signaling by regulating the interaction of TLR4 with caveolin-1. J Immunol. 2009;182(6):3809–3818.
108. Rocuts F, Ma Y, Zhang X, et al. Carbon monoxide suppresses membrane expression of TLR4 via myeloid differentiation factor-2 in betaTC3 cells. J Immunol. 2010;185(4):2134–2139.
109. Riquelme SA1, Bueno SM, Kalergis AM. Carbon monoxide down-modulates Toll-like receptor 4/MD2 expression on innate immune cells and reduces endotoxic shock susceptibility. Immunology. 2015;144(2):321–332.
110. Jung SS, Moon JS, Xu JF, et al. Carbon monoxide negatively regulates NLRP3 inflammasome activation in macrophages. Am J Physiol Lung Cell Mol Physiol. 2015;308(10):L1058–L1067.
111. Wang P, Huang J, Li Y, et al. Exogenous carbon monoxide decreases sepsis-induced acute kidney injury and inhibits NLRP3 inflammasome activation in rats. Int J Mol Sci. 2015;16(9):20595–20608.
112. Jiang L, Fei D, Gong R, et al. CORM-2 inhibits TXNIP/NLRP3 inflammasome pathway in LPS-induced acute lung injury. Inflamm Res. 2016;65(11):905–915.
113. Zhang W, Tao A, Lan T, et al. Carbon monoxide releasing molecule-3 improves myocardial function in mice with sepsis by inhibiting NLRP3 inflammasome activation in cardiac fibroblasts. Basic Res Cardiol. 2017;112(2):16. doi: 10.1007
114. Wegiel B, Gallo DJ, Raman KG, et al. Nitric oxide-dependent bone marrow progenitor mobilization by carbon monoxide enhances endothelial repair after vascular injury. Circulation. 2010;2;121(4):537–548.
115. Zuckerbraun BS, Chin BY, Wegiel B, et al. Carbon monoxide reverses established pulmonary hypertension. J Exp Med. 2006;203(9):2109–2119.
116. Beckman J, Belcher JD, Vineyard JV, et al. Inhaled carbon monoxide reduces leukocytosis in a murine model of sickle cell disease. Am J Physiol Heart Circ Physiol. 2009;297:H1243–H1253.
117. Bains SK, Foresti R, Howard J, Atwal S, Green CJ, Motterlini R. Human sickle cell blood modulates endothelial heme oxygenase activity: effects on vascular adhesion and reactivity. Arterioscler Thromb Vasc Biol. 2010;30(2):305–312.
118. Belcher JD, Mahaseth H, Welch TE, Otterbein LE, Hebbel RP, Vercellotti GMJ. Heme oxygenase-1 is a modulator of inflammation and vaso-occlusion in transgenic sickle mice. J Clin Invest. 2006;116:808–816.
119. Bernaudin F, Verlhac S, Freard F, et al. Multicenter prospective study of children with sickle cell disease: radiographic and psychometric correlation. J Child Neurol. 2000;15:333–343.
120. Kassim AA, Pruthi S, Day M, et al. Silent cerebral infarcts and cerebral aneurysms are prevalent in adults with sickle cell anemia. Blood. 2016;127:2038–2040.
121. Ohene-Frempong K, Weiner SJ, Sleeper LA, et al. Cerebrovascular accidents in sickle cell disease: rates and risk factors. Blood. 1998;91:288–294.
122. Adams RJ, McKie VC, Hsu L, et al. Prevention of a first stroke by transfusions in children with sickle cell anemia and abnormal results on transcranial doppler ultrasonography. N Engl J Med. 1998;339:5–11.
123. Ware RE, Helms RW, et al. Stroke with transfusion changing to hydroxyurea (SWiTCH). Blood. 2012;118:3925–3932.
124. Becker KJ, Kalil AJ, Tanzi P, et al. Autoimmune responses to the brain after stroke are associated with worse outcome. Stroke. 2011;42:2763–2769.
125. Klaus JA, Kibler KK, Abuchowski A, Koehler RC. Early treatment of transient focal cerebral ischemia with bovine PEGylated carboxy hemoglobin transfusion. Artif Cells, Blood Substit Immobil Biotechnol. 2010;38:223–229.
126. Panahian N, Yoshiura M, Maines MD. Overexpression of heme oxygenase-1 is neuroprotective in a model of permanent middle cerebral artery occlusion in transgenic mice. J Neurochem. 1999;72:1187–1203.
127. Wang B, Cao W, Biswal S, Dore S. Carbon monoxide-activated Nrf2 pathway leads to protection against permanent focal cerebral ischemia. Stroke. 2011;42:2605–2610.
128. Chao XD, Ma YH, Luo P, et al. Up-regulation of heme oxygenase-1 attenuates brain damage after cerebral ischemia via simultaneous inhibition of superoxide production and preservation of NO bioavailability. Exp Neurol. 2013;239:163–169.
129. Zhang J, Cao S, Kwansa H, Crafa D, Kibler KK, Koehler RC. Transfusion of hemoglobin-based oxygen carriers in the carboxy state is beneficial during transient focal cerebral ischemia. J Appl Physiol. 2012;113:1709–1717.
130. Ahmad AS, Zhuang H, Dore S. Heme oxygenase-1 protects brain from acute excitotoxicity. Neuroscience. 2006;141:1703–1708.
131. Braun JS, Jander S, Schroeter M, Witte OW, Stoll G. Spatiotemporal relationship of apoptotic cell death to lymphomonocytic infiltration in photochemically induced focal ischemia of the rat cerebral cortex. Acta Neuropathol. 1996;92:255–263.
132. Jander S, Kraemer M, Schroeter M, Witte OW, Stoll G. Lymphocytic infiltration and expression of intercellular adhesion molecule-1 in photochemically induced ischemia of the rat cortex. J Cereb Blood Flow Metab. 1995;15:42–51.
133. van Zwam M, Huizinga R, Melief MJ, et al. Brain antigens in functionally distinct antigen-presenting cell populations in cervical lymph nodes in MS and EAE. J Mol Med. 2009;87:273–286.
134. Planas AM, Gomez-Choco M, Urra X, Gorina R, Caballero M, Chamorro A. Brain-derived antigens in lymphoid tissue of patients with acute stroke. J Immunol. 2012;188:2156–2163.
135. Kallen B, Nilsson O, Thelin C. Effect of encephalitogenic protein on migration in agarose of leukoytes from patients with multiple sclerosis. A longitudinal study of patients with relapsing multiple sclerosis or with cerebral infarction. Acta Neurol Scand. 1977;55:47–56.
136. Youngchaiyud U, Coates AS, Whittingham S, Mackay IR. Cellular-immune response to myelin protein: absence in multiple sclerosis and presence in cerebrovascular accidents. Aust N Z J Med. 1974;4:535–538.
137. WangWZ, Olsson T, Kostulas V, Hojeberg B, Ekre HP, Link H. Myelin antigen reactive T cells in cerebrovascular diseases. Clin Exp Immunol. 1992;88:157–162.
138. Bornstein NM, Aronovich B, Korczyn AD, Shavit S, Michaelson DM, Chapman J. Antibodies to brain antigens following stroke. Neurology. 2001;56:529–530.
139. Dambinova SA, Khounteev GA, Izykenova GA, Zavolokov IG, Ilyukhina AY, Skoromets AA. Blood test detecting autoantibodies to N-methyl-D-aspartate neuroreceptors for evaluation of patients with transient ischemic attack and stroke. Clin Chem. 2003;49:1752–1762.
140. Kalev-Zylinska ML, Symes W, Little KC, et al. Stroke patients develop antibodies that react with components of N-methyl-D-aspartate receptor subunit 1 in proportion to lesion size. Stroke. 2013;44:2212–2219.
141. Becker KJ, Kindrick DL, Lester MP, Shea C, Ye ZC. Sensitization to brain antigens after stroke is augmented by lipopolysaccharide. J Cereb Blood Flow Metab. 2005;25:1634–1644.
142. Gee JM, Kalil A, Thullbery M, Becker KJ. Induction of immunologic tolerance to myelin basic protein prevents central nervous system autoimmunity and improves outcome after stroke. Stroke. 2008;39:1575–1582.
143. Gee JM, Zierath D, Hadwin J, et al. Long term immunologic consequences of experimental stroke and mucosal tolerance. Exp Transl Stroke Med. 2009;1:3.
144. Zierath D, Schulze J, Kunze A, et al. The immunologic profile of adoptively transferred lymphocytes influences stroke outcome of recipients. J Neuroimmunol. 2013;263:28–34.
145. Shichita T, Sugiyama Y, Ooboshi H, et al. Pivotal role of cerebral interleukin-17-producing gammadeltaT cells in the delayed phase of ischemic brain injury. Nat Med. 2009;15:946–950.
146. Konoeda F, Shichita T, Yoshida H, et al. Therapeutic effect of IL-12/23 and their signaling pathway blockade on brain ischemia model. Biochem Biophys Res Commun. 2010;402:500–506.
147. Gelderblom M, Weymar A, Bernreuther C, et al. Neutralization of the IL-17 axis diminishes neutrophil invasion and protects from ischemic stroke. Blood. 2012;120:3793–3802.
148. Swardfager W, Winer DA, Herrmann N, Winer S, Lanctot KL. Interleukin-17 in post-stroke neurodegeneration. Neurosci Biobehav Rev. 2013;37:436–447.
149. Hu Y, Zheng Y, Wu Y, Ni B, Shi S. Imbalance between IL-17A-producing cells and regulatory T cells during ischemic stroke. Mediators Inflamm. 2014;2014:813045.
150. Becker KJ, McCarron RM, Ruetzler C, et al. Immunologic tolerance to myelin basic protein decreases stroke size after transient focal cerebral ischemia. Proc Natl Acad Sci USA. 1997;94:10873–10878.
151. Chora AA, Fontoura P, Cunha A, et al. Heme oxygenase-1 and carbon monoxide suppress autoimmune neuroinflammation. J Clin Invest. 2007;117:438–447.
152. Tardif V, Riquelme SA, Remy S, et al. Carbon monoxide decreases endosome-lysosome fusion and inhibits soluble antigen presentation by dendritic cells to T cells. Eur J Immunol. 2013;43:2832–2844.
153. Bani-Hani MG, Greenstein D, Mann BE, Green CJ, Motterlini R. Modulation of thrombin-induced neuroinflammation in BV-2 microglia by carbon monoxide-releasing molecule 3. J Pharmacol Exp Ther. 2006;318:1315–1322.
154. Yabluchansky A, Sawle P, Homer-Vanniasinkam S, Green CJ, Foresti R, Motterlini R. CORM-3, a carbon monoxide-releasing molecule, alters the inflammatory response and reduces brain damage in a rat model of hemorrhagic stroke. Crit Care Med. 2012;40: 544–552.
155. Zimmermann A, Leffler CW, Tcheranova D, Fedinec AL, Parfenova H. Cerebroprotective effects of the CO-releasing releasing molecule CORM-A1 against seizure-induced neonatal vascular injury. Am J Physiol Heart Circ Physiol. 2007;293:H2501–H2507.
156. Mahan VL, Zurakowski D, Otterbein LE, Pigula FA. Inhaled carbon monoxide provides cerebral cytoprotection in pigs. PLoS One. 2012;7(8):e41982.
157. Choi YK, Maki T, Mandeville ET, et al. Dual effects of carbon monoxide on pericytes and neurogenesis in traumatic brain injury. Nat Med. 2016;22(11):1335–1441.
158. Motterlini R, Clark JE, Foresti R, Sarathchandra P, Mann BE, Green CJ. Carbon monoxide-releasing molecules: characterization of biochemical and vascular activities. Circ Res. 2002;90:E17–E24.
159. Ji X, Damera K, Zheng Y, Yu B, Otterbein LE, Wang B. Toward carbon-monoxide-based therapeutics: Critical drug delivery and developmentability issues. J Pharm Sci. 2016;105:406–416.
160. Winburn IC, Gunatunga K, McKernan RD, Walker RJ, Sammut IA, Harrison JC. Cell damage following carbon monoxide releasing molecule exposure: implications for therapeutic applications. Basic Clin Pharmacol Toxicol. 2012;111:31–41.
161. Inaba H, Fujita K, Ueno T. Design of biomaterials for intracellular delivery of carbon monoxide. Biomater Sci. 2015;3:1423–1438.
162. Wilson JL, Kobeissi S, Oudir S, et al. Design and synthesuis of new hybrid molecules that activates the transcription factor Nrf2 and simultaneously release carbon monoxide. Chem Eur J. 2014;20:14698–14704.
163. Natanson C, Kem SJ, Lurie P, Banks SM, Wolfe SM. Cell-free hemoglobin-based blood substitutes and risk of myocardial infarction and death: a meta-analysis. JAMA. 2008;299:2304–2312.
164. Alayash AI. Hemoglobin-based blood substitutes and the treatment of sickle cell disease: more harm than help? Biomolecules. 2017; 47(1): pii E2.
165. Gomperts E, Forman HJ, Liu H, Lee M. The pharmacokinetic evaluation of oral administered carbon monoxide instilled in a liquid formulation (CO-LF) to rats to determine carbon monoxide hemoglobin levels with potential efficacy in patients with Sickle Cell Disease (SCD). Am Soc Hematol. 2013. [Abstract]
166. Otterbein LE, Foresti R, Motterlini R. Heme oxygenase-1 and carbon monoxide in the heart: The balancing act between danger signaling and pro-survival. Circ Res. 2016;118(12):1940–1959.
167. Coburn RF. Carbon monoxide uptake in the gut. Ann N Y Acad Sci. 1968;150:13–21.
168. Becker KJ, Zierath D, Shen A, et al. (2017, March). Oral Carbon Monoxide as a Treatment for Stroke. Poster session presented at the International Stroke Conference, Houston, TX.
169. Belcher JD, Gomperts E, Levy H, Otterbein L, Vercellotti GM. HBI-002, an oral carbon monoxide therapeutic, is a modulator of vaso-occlusion in transgenic sickle cell mice. Found Sickle Cell Dis Res. 2017. [Abstract]